TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
Rheumatology Advisor5d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Mena FN6d
TREMFYA® (Guselkumab) Receives Positive CHMP Opinion For Treatment Of Patients With Moderately To Severely Active Crohn’S Disease
3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn's disease”, said Mark ...
PMLive2d
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
pharmaphorum5d
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease approval
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease ... Johnson's Tremfya (guselkumab), and ...